Report Sections

See All Reports

  • HP:0001370: Rheumatoid arthritis
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001370: Rheumatoid arthritis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (41)


    Name (Synonyms) Correlation
    drug4162 Stools Wiki 0.26
    drug4454 Traditional antirheumatic drugs Wiki 0.26
    drug729 C3+ Holter Monitor Wiki 0.26
    Name (Synonyms) Correlation
    drug734 CAP-1002 Wiki 0.26
    drug4866 blood tests Wiki 0.26
    drug3353 Pravastatin Wiki 0.26
    drug5136 placebo rinse Wiki 0.26
    drug2001 Hydroxychloroquine/Chloroquine Wiki 0.26
    drug751 CETA Short Session (CSS) Wiki 0.26
    drug3436 Psychoeducation and Safety Wiki 0.26
    drug2478 MSB11456 Wiki 0.26
    drug1432 EU-approved RoActemra Wiki 0.26
    drug764 CK0802 Wiki 0.26
    drug1495 Enbrel Wiki 0.26
    drug727 C21 Wiki 0.26
    drug765 CLBS119 Wiki 0.26
    drug741 CCP Wiki 0.26
    drug1668 Filgotinib Wiki 0.26
    drug723 Buspirone 10 Mg Oral Tablet Wiki 0.26
    drug743 CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc Wiki 0.26
    drug285 Alternating face-to-face medical visits and video medical consultations Wiki 0.26
    drug744 CD24Fc Wiki 0.26
    drug754 CGB-S-100 Wiki 0.26
    drug4508 Triazolam 0.25 MG Oral Tablet Wiki 0.26
    drug4034 Sofusa DoseConnect Wiki 0.26
    drug758 CHLORPROMAZINE (CPZ) Wiki 0.26
    drug3932 Serological analyses to be lead on a pre-existing biobank Wiki 0.26
    drug1633 Face-to-face medical visits Wiki 0.26
    drug760 CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki 0.26
    drug716 Bucillamine Wiki 0.18
    drug2763 Nasopharyngeal swabs Wiki 0.18
    drug697 Brequinar Wiki 0.18
    drug1737 GLPG3970 Wiki 0.18
    drug413 Atorvastatin Wiki 0.15
    drug3724 Rosuvastatin Wiki 0.13
    drug5171 questionnaire assesment Wiki 0.12
    drug4104 Standard of Care (SOC) Wiki 0.12
    drug3215 Placebo Administration Wiki 0.12
    drug3195 Placebo Wiki 0.07
    drug3273 Placebo oral tablet Wiki 0.04
    drug1950 Hydroxychloroquine Wiki 0.03

    Correlated MeSH Terms (19)


    Name (Synonyms) Correlation
    D001172 Arthritis, Rheumatoid NIH 1.00
    D001168 Arthritis NIH 0.87
    D025241 Spondylarthritis NIH 0.39
    Name (Synonyms) Correlation
    D013166 Spondylitis NIH 0.26
    D013167 Spondylitis, Ankylosing NIH 0.26
    D015535 Arthritis, Psoriatic NIH 0.23
    D001167 Arteritis NIH 0.18
    D003095 Collagen Diseases NIH 0.17
    D012216 Rheumatic Diseases NIH 0.16
    D011111 Polymyalgia Rheumatica NIH 0.15
    D013700 Giant Cell Arteritis NIH 0.15
    D012859 Sjogren's Syndrome NIH 0.13
    D001327 Autoimmune Diseases NIH 0.12
    D008180 Lupus Erythematosus, Systemic NIH 0.11
    D059350 Chronic Pain NIH 0.07
    D003141 Communicable Diseases NIH 0.04
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (5)


    Name (Synonyms) Correlation
    HP:0001369 Arthritis HPO 0.87
    HP:0012089 Arteritis HPO 0.18
    HP:0002960 Autoimmunity HPO 0.12
    Name (Synonyms) Correlation
    HP:0002725 Systemic lupus erythematosus HPO 0.11
    HP:0012532 Chronic pain HPO 0.07

    Clinical Trials

    Navigate: Correlations   HPO

    There are 15 clinical trials


    1 IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT

    This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking anti-malarial medications compared to those who do not. This registry includes approximately 2500 northern Alberta patients with inflammatory arthritis who receive highly complex therapies which may be associated with side effects. This program of data collection and research has been evaluating the effectiveness and safety as well as associated health care costs of rheumatoid and psoriatic arthritis patients since 2004. The principle investigators are based at the University of Alberta while the co-investigators are academic rheumatologists at the University of Alberta. The registry has approximately 900 patients taking anti-malarials combined with their complex therapies and ~ 1500 not on anti-malarials in combination with their complex therapies. We aim to perform a case control study evaluating the impact of anti-malarial drugs (eg. hydroxychloroquine and chloroquine) on the development of COVID-19 compared to those patients who are not on anti-malarial drugs over the next 6-12 months. In addition to frequent e-mail surveys screening for the clinical symptoms of COVID-19 and understanding their concomitant arthritis medication use, we will compare the healthcare outcomes of both groups of arthritis patients with and without COVID-19 for the duration of the pandemic. This information will provide critical information beyond an anecdotal level on whether or not anti-malarials truly provide a protective benefit against COVID-19 or reduce the severity of infection. A blood sample from all participants (Covid-19 positive and negative) will be drawn approximately six months into the study for measurement of antibodies to Covid-19 and possible blood types and HLA alleles. Additionally, this study will be linked to another study "Persistence of SARS-Cov2 in immunocompromised patients" which will specifically evaluate COVID-19 serology and nasopharyngeal swab findings in the subset of patients who develop COVID-19.

    NCT04347798
    Conditions
    1. Covid-19 Infection
    2. Rheumatoid Arthritis
    3. Psoriatic Arthritis
    4. Hydroxychloroquine
    Interventions
    1. Other: Hydroxychloroquine/Chloroquine
    MeSH:Infection Communicable Diseases Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Number of patients developing signs and symptoms of Covid-19 or other infections

    Measure: Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group

    Time: 12 months

    Secondary Outcomes

    Description: Number of patients developing Covid-19 infection

    Measure: Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group

    Time: 12 months

    Description: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action

    Measure: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action

    Time: 12 months

    Other Outcomes

    Description: Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure

    Measure: Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients

    Time: 6 months
    2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

    Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

    NCT04351399
    Conditions
    1. Sars-CoV2
    2. Rheumatic Diseases
    3. Rheumatoid Arthritis
    4. Chronic Pain
    Interventions
    1. Other: questionnaire assesment
    MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
    HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Measure: Frequency of RA patients with emotional impact (feeling of isolation)

    Time: maximum 1 week from baseline on

    Secondary Outcomes

    Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

    Measure: self-reported questionnaire for painful

    Time: maximum 1 week from baseline on
    3 Antimalarial and Covid 19 in Rheumatoid Arthritis

    The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

    NCT04389320
    Conditions
    1. Rheumatoid Arthritis
    Interventions
    1. Drug: Hydroxychloroquine
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: serum level

    Measure: immunoglobulin mesurement

    Time: 1 month
    4 Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

    The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

    NCT04393233
    Conditions
    1. Rheumatoid Arthritis
    2. COVID
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

    Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

    Time: 1 Day
    5 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

    The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

    NCT04397237
    Conditions
    1. COVID-19
    2. Systemic Lupus Erythematosus
    3. Sjogren's Syndrome
    4. Axial Spondyloarthritis
    5. Rheumatoid Arthritis
    6. Giant Cell Arteritis
    MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: ELISA tests for COVID-19 antibodies

    Measure: COVID-19 seroconversion

    Time: 1 day, during routine blood collection

    Description: Case report form filled by the health professional

    Measure: COVID-19 infection

    Time: During medical visit or phone consultation, up to 2 hours

    Secondary Outcomes

    Description: Descriptive analysis for each disease's rate

    Measure: Seroconversion rate by disease

    Time: 1 day, during routine blood collection

    Description: Descriptive analysis for each country's rate

    Measure: Penetration across Europe

    Time: 1 day, during routine blood collection

    Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

    Measure: COVID-19 severity

    Time: During medical visit, up to 1 hour

    Description: Descriptive analysis for overall and COVID-19-linked mortality rates

    Measure: COVID-19 mortality rate

    Time: During contact with family members, up to 1 hour

    Description: Case report form filled by the health professional

    Measure: COVID-19 impact on immunomodulatory treatment

    Time: During medical visit, up to 1 hour

    Description: Case report form filled by the patient

    Measure: Patient-reported flares

    Time: During medical visit, up to 1 hour

    Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

    Measure: Patient's fears towards COVID-19

    Time: During medical visit, up to 1 hour

    Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

    Measure: Patient's beliefs in their medicines towards COVID-19

    Time: During medical visit, up to 1 hour
    6 Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients

    Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.

    NCT04407559
    Conditions
    1. COVID-19
    2. Rheumatoid Arthritis
    Interventions
    1. Other: Serological analyses to be lead on a pre-existing biobank
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Evaluate the false positive results rate when using each one of the three SARS-CoV-2 serology tests in patients with rheumatoid factor plasma levels, so as to define the specificity of these tests in this RA population. all serum samples will be tested by the 3 different immunoassays. The RF plasma levels have already been measured (routine exam) and are written in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the question.

    Measure: Evaluate the false positive results rate

    Time: 4 months

    Secondary Outcomes

    Description: Characterize the RF isotype (IgG, IgM or IgA) associated with the false positivity of the test.all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

    Measure: Characterize the RF isotype (IgG, IgM or IgA) associated

    Time: 4 months

    Description: Determine the influence of RA on the false positivity rate in subjects with negative RF titer. All serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

    Measure: Determine the influence of RA on the false positivity rate in subjects

    Time: 4 months

    Description: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

    Measure: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test

    Time: 4 months

    Description: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

    Measure: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test

    Time: 4 months
    7 Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study

    Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.

    NCT04434118
    Conditions
    1. Rheumatoid Arthritis
    2. COVID
    Interventions
    1. Drug: Traditional antirheumatic drugs
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Realtion between hydroxychloroquine use and COVID-19 infection

    Measure: The risk of COVID-19 infection among RA patients

    Time: 12 week

    Secondary Outcomes

    Description: Number of cases and number of hospitalization days

    Measure: The incidence of hospitalization for Covid-19 patients.

    Time: 12 week
    8 A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)

    The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis. Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.

    NCT04512001
    Conditions
    1. Rheumatoid Arthritis
    Interventions
    1. Drug: MSB11456
    2. Drug: EU-approved RoActemra
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

    Time: Baseline; Week 24

    Secondary Outcomes

    Measure: Change from Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

    Time: Baseline; Week 52

    Measure: Number of Participants with 20% Improvement in American College of Rheumatology (ACR20) Response

    Time: Week 24

    Measure: Number of Participants who Experienced One or More Treatment-Emergent Adverse Event (TEAE)

    Time: Baseline to end of study, up to Week 63

    Measure: Number of Participants who Experienced One or More Serious Adverse Event (SAE)

    Time: Baseline to end of study, up to Week 63

    Measure: Number of Participants with Positive Anti-Drug Antibodies (ADAs)

    Time: Week 2; Week 55

    Measure: Anti-Drug Antibodies (ADAs) Titer Levels

    Time: Week 2; Week 55

    Measure: Number of Participants with Confirmed Neutralizing Antibodies (NAb)

    Time: Week 2; Week 55
    9 Seroprevalence and Clinical Expression of SARS-CoV-2 Infection in Patients With Chronic Inflammatory Rheumatisms and Impact of Immuno-suppressive Drugs on the Persistence of Anti-SARS-CoV2 Antibodies During Two Years of Follow-up

    A better understanding of the different phenotypes of COVID 19 in patients with inflammatory rheumatisms, and the persitence of antibodies against SARS CoV-2 in these patients under immunosuppressive drugs are required to propose appropriated recommendations for these patients in order to guide the strategy of vaccination in this immune-depressed population who is not immunized.

    NCT04530682
    Conditions
    1. Rheumatoid Arthritis
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Variation of anti-SARS-CoV2 antibodies titers between baseline

    Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms

    Time: 6 months

    Description: Variation of anti-SARS-CoV2 antibodies titers between baseline

    Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms

    Time: 12 months

    Secondary Outcomes

    Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

    Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

    Time: 6 months

    Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

    Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

    Time: 12 months

    Description: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals

    Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion

    Time: 24 months
    10 Impact of a Hybrid Medical Care Model (Face-to-face Medical Visits Alternating With Video Medical Consultations) in the Rheumatoid Arthritis Patient-reported-outcomes Measures: A Non-inferiority Study

    The COVID-19 outbreak has affected health care of patients with rheumatic diseases; telemedicine might help to assist patients. The primary objective is to determine if a hybrid medical care model, which consists of alternating face-to-face medical visits and video medical consultations, is not inferior, in terms of the Patient Reported Outcomes measures (PROMs), to the face-to-face medical care model, among rheumatoid arthritis (RA) outpatients. We also aim to investigate if adherence to RA-related treatment (considered a surrogate of patient´s education) might be improved when patients are re-integrated to the health care system, irrespective of the health care model. In Mexico, COVID-19 pandemic still uncontrolled. Our Institution provides health care to 1500 RA patients/year and up to August 2020, it is estimated that 500 RA patients might be affected, which is our target audience. Reinstalling institutional health care provision is challenging. This a non-inferiority, cross-over study, with 2 intervention arms. Patients will be randomized to 1. Six months of usual medical care model, followed by 4 months of a control period, and 6 months of hybrid medical care model, or 2. Six months of hybrid medical care model, followed by 4 months of a control period, and 6 months of usual medical care model. The following PROMs will be assessed at specific time points: disease activity/disease severity (RAPID-3), disability (HAQ-DI), quality of life (WHOQOL-BREF), patient satisfaction with the medical care model (questionnaire locally developed), patient´s adherence to medical care (missed scheduled visits) and patient´s adherence to RA-related treatment (the Compliance-Questionnaire).

    NCT04558905
    Conditions
    1. Rheumatoid Arthritis
    2. Telehealth
    Interventions
    1. Other: Face-to-face medical visits
    2. Other: Alternating face-to-face medical visits and video medical consultations
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: The disease activity measured by a RAPID-3 instrument

    Measure: Rheumatoid arthritis patient´s disease activity

    Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)

    Description: Quality of life measured by a WHOQOL-BREF instrument

    Measure: Rheumatoid arthritis patient´s quality of life

    Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)

    Description: Disability measured by a HAQ-DI instrument

    Measure: Rheumatoid arthritis patient's disability

    Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)

    Secondary Outcomes

    Description: Questionnaire locally developed

    Measure: Satisfaction with medical care

    Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)

    Description: Number of missed scheduled visits

    Measure: Patient´s adherence to medical care

    Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)
    11 Phase 1b Proof-of-concept, Open-label Study to Assess the Safety and Pilot Efficacy of Enbrel® Administered by the Sofusa® DoseConnect™ Delivery System for the Treatment of Rheumatoid Arthritis

    This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly. The dose will be increased to 50 mg if the dose escalation criteria are met during the dose escalation phase of the study.

    NCT04559412
    Conditions
    1. Rheumatoid Arthritis
    Interventions
    1. Device: Sofusa DoseConnect
    2. Drug: Enbrel
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Incidence and severity of adverse events and their relationships to SOFUSA administration

    Measure: Incidence and severity of adverse events and their relationships to SOFUSA administration

    Time: Baseline through Week 12

    Secondary Outcomes

    Description: Change from Baseline in DAS28(CRP) score at Week 12

    Measure: Change in Disease Activity Score 28-joint count C reactive protein (DAS28(CRP))

    Time: Baseline to Week 12

    Description: Change from Baseline in DAS28(CRP) score over time

    Measure: Change in DAS28(CRP) score over time

    Time: Baseline through Week 12

    Description: Change from Baseline in DAS28(ESR) score over time

    Measure: Change in Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28(ESR)) over time

    Time: Baseline through Week 12

    Description: Change from Baseline in SDAI score over time

    Measure: Change in Simplified Disease Activity Index (SDAI) score over time

    Time: Baseline through Week 12

    Description: Change from Baseline in CDAI score over time

    Measure: Change in Clinical Disease Activity Index (CDAI) score over time

    Time: Baseline through Week 12

    Description: Proportion of patients with DAS28(CRP) score < 2.9 over time

    Measure: Proportion of patients with low disease activity (LDA) over time as assessed by the DAS28(CRP)

    Time: Baseline through Week 12

    Description: Proportion of patients with DAS28(ESR) score ≤ 3.2 over time

    Measure: Proportion of patients with LDA over time as assessed by the DAS28(ESR)

    Time: Baseline through Week 12

    Description: Proportion of patients with SDAI score ≤ 11.0 over time

    Measure: Proportion of patients with LDA over time as assessed by the SDAI

    Time: Baseline through Week 12

    Description: Proportion of patients with CDAI score ≤ 10 over time

    Measure: Proportion of patients with LDA over time as assessed by the CDAI

    Time: Baseline through Week 12

    Description: Proportion of patients achieving ACR20/50/70 response over time

    Measure: Proportion of patients achieving ACR20/50/70 response over time

    Time: Baseline through Week 12

    Description: Proportion of patients achieving moderate or good EULAR response over time

    Measure: Proportion of patients achieving moderate or good EULAR response over time

    Time: Baseline through Week 12

    Description: Proportion of patients achieving a MCID of 0.22 in HAQ-DI over time

    Measure: Proportion of patients achieving a minimally clinically important difference (MCID) of 0.22 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) over time

    Time: Baseline through Week 12
    12 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).

    NCT04577781
    Conditions
    1. Arthritis, Rheumatoid
    Interventions
    1. Drug: GLPG3970
    2. Drug: Placebo
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Measure: Change From Baseline in Disease Activity Score Based on 28 Joints (DAS28) (C-reactive protein [CRP]) at Week 6

    Time: Baseline and Week 6

    Secondary Outcomes

    Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) by Severity

    Time: Screening up to Follow-up (Week 11)

    Measure: Observed Plasma Trough Concentration (Ctrough) of GLPG3970

    Time: Predose (within 30 minutes prior to dosing) on Days 15, 29 and 43
    13 Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments

    The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.

    NCT04584541
    Conditions
    1. Spondyloarthritis
    2. Rheumatoid Arthritis
    3. Covid19
    Interventions
    1. Biological: blood tests
    2. Biological: Nasopharyngeal swabs
    3. Biological: Stools
    MeSH:Arthritis Arthritis, Rheumatoid Spondylarthritis
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA

    Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs

    Time: up to Day 30

    Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA

    Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs

    Time: between Day 30 and Day 90

    Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

    Time: up to Day 30

    Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

    Time: between Day 30 and Day 90

    Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

    Time: 6 Months

    Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

    Time: 12 Months

    Measure: Detection and quantification of IgG, IgM and IgA specific for SarS-Cov-2 N and S proteins in blood

    Time: 24 Months

    Measure: Isolation and characterization of B and T lymphocytes in blood

    Time: up to Day 30

    Measure: Isolation and characterization of B and T lymphocytes in blood

    Time: between Day 30 and Day 90

    Measure: Isolation and characterization of B and T lymphocytes in blood

    Time: 6 Months

    Measure: Isolation and characterization of B and T lymphocytes in blood

    Time: 12 Months

    Measure: Isolation and characterization of B and T lymphocytes in blood

    Time: 24 Months
    14 A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

    The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.

    NCT04608344
    Conditions
    1. Rheumatoid Arthritis
    Interventions
    1. Drug: Atorvastatin
    2. Drug: Pravastatin
    3. Drug: Rosuvastatin
    4. Drug: Filgotinib
    MeSH:Arthritis Arthritis, Rheumatoid
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Measure: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of ATV, PRA, and ROS

    Time: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)

    Measure: Area Under the Concentration Versus Time Curve Extrapolated to Infinite Time (AUCinf) of ATV, PRA, and ROS

    Time: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)

    Measure: Maximum Observed Plasma Concentration (Cmax) for ATV, PRA, and ROS

    Time: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose (Sequence AB: Days 1 and 12 up to 48 hours; Days 3 and 14 up to 72 hours. Sequence BA: Days 6 and 18 up to 48 hours; Days 8 and 20 up to 72 hours)

    Secondary Outcomes

    Measure: Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time: Up to 26 days for sequence AB and up to 29 days for sequence BA

    Measure: Percentage of Participants Experiencing Laboratory Abnormalities

    Time: Up to 26 days for sequence AB and up to 29 days for sequence BA
    15 Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

    The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

    NCT04655612
    Conditions
    1. COVID-19
    2. SARS-CoV Infection
    3. Rheumatoid Arthritis
    4. Spondyloarthritis
    5. Ankylosing Spondylitis
    6. Psoriatic Arthritis
    MeSH:Infection Communicable Diseases Spondylitis Coronavirus Infections Severe Acute Respiratory Syndrome Arthritis Arthritis, Rheumatoid Arthritis, Psoriatic Spondylitis, Ankylosing Rheumatic Diseases Spondylarthritis Collagen Diseases
    HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

    Primary Outcomes

    Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

    Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis

    Time: 1 day

    Secondary Outcomes

    Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

    Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.

    Time: 1 day

    Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

    Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease

    Time: 1 day

    Description: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

    Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics

    Time: 1 day

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook